Browsing by Author "Gallardo, Jorge"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience
    (2022) Cordova-Delgado, Miguel; Pinto, Mauricio P.; Regonesi, Carlos; Cereceda, Luis; Reyes, Jose Miguel; Itriago, Laura; Majlis, Alejandro; Rodriguez, Pablo; Fassler, Andre; Mahave, Mauricio; Leon, Maria Elisa; Gallardo, Jorge; Rodriguez, Maria Paz Z.; Berkovits, Alejandro; Manque, Patricio; Rios, Juvenal A.; Garcia-Bloj, Benjamin; Garrido, Marcelo
    Major advances in sequencing technologies and targeted therapies have accelerated the incorporation of oncology into the era of precision medicine and "biomarker-driven" treatments. However, the impact of this approach on the everyday clinic has yet to be determined. Most precision oncology reports are based on developed countries and usually involve metastatic, hard-to-treat or incurable cancer patients. Moreover, in many cases race and ethnicity in these studies is commonly unreported and real-world evidence in this topic is scarce. Herein, we report data from a total of 202 Chilean advanced stage refractory cancer patients. Retrospectively, we collected patient data from NGS tests and IHC in order to determine the proportion of patients that would benefit from targeted treatments. Overall >20 tumor types were included in our cohort and 37% of patients (n = 74) displayed potentially actionable alterations, including on-label, off-label and immune checkpoint inhibitor recommendations. Our findings were in-line with previous reports such as the cancer genome atlas (TCGA). To our knowledge, this is the first report of its kind in Latin America delivering real-world evidence to estimate the percentage of refractory tumor patients that might benefit from precision oncology. Although this approach is still in its infancy in Chile, we strongly encourage the implementation of mutational tumor boards in our country in order to provide more therapeutic options for advanced stage refractory patients.
  • Thumbnail Image
    Item
    Radio and chemotherapy in gallbladder cancer. A Latin American Consensus
    (SOC MEDICA SANTIAGO, 2012) Gonzalez M, Pablo; Baeza, Ramon; Mueller, Bettina; Gallardo, Jorge; Harbst, Hans; Bustos, Marisa; Garcia, Cesar; Giannini, Osvaldo; Cartes, Raul; Vines, Eugenio; Carrasco, Paula
    No randomized controlled trials have been conducted in gallbladder cancer to establish standard treatments. We therefore conducted the first Latin American Consensus meeting for the management of gallbladder cancer. In this paper we report the conclusions of the experts' panel for (neo) adjuvant treatment of resectable gallbladder cancer. These are based on the review of the literature, the discussion of the participating experts and the vote of the assistants (surgical oncologists, medical oncologists, radiation oncologists and others). The reviewed topics were the role or adjuvant radiochemotherapy in T1bN0M0, T2-3 N0-1 M0 and T4 N0-1 M0 disease and doses, schedules and drugs for radiochemotherapy. (Rev Med Chile 2012; 140: 1060-1066).
  • Thumbnail Image
    Item
    Recomendaciones sobre el manejo del cáncer de páncreas tipo adenocarcinoma en Latinoamérica. Reunión del Consenso del Simposio Latinoamericano de Gastroenterología Oncológica (SLAGO) y de la Asociación Ibero Latinoamericana de Terapia Radiante (ALATRO), Viña del Mar, Chile 2015
    (2016) Caglevic, Christian; Gallardo, Jorge; De la Torre, Marcela; Mahave, Mauricio; Müller, Bettina; Solé, Sebastián; Moscoso, Yuri; De La Fuente, Hernán; Roa Strauch, Juan Carlos Enrique; Torres Montes, Paula Javiera